http://www.xconomy.com/boston/2009/03/03/vertex-acquires-virochem-for-375m-to-make-cocktail-treatments-for-hepatitis-c/ Business + Technology in the Exponential Economy Mon, 23 Nov 2009 06:44:11 -0600 http://wordpress.org/?v=2.8.6 hourly 1 http://www.xconomy.com/boston/2009/03/03/vertex-acquires-virochem-for-375m-to-make-cocktail-treatments-for-hepatitis-c/comment-page-1/#comment-48662 Overnight - ViroChem Acquired, Acusphere Swings Axe | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries Wed, 04 Mar 2009 14:01:15 +0000 http://www.xconomy.com/?p=14732#comment-48662 [...] -Vertex has acquired ViroChem Pharma for $375M. The deal includes $100M in cash for Canada-based ViroChem plus 9.9M Vertex shares. Vertex is interested in two of Virochem’s non-nucleoside HCV NS5B polymerase inhibitors, VCH-759, which is in a Phase 2 trial, and VCH-222, which is in a Phase 1. Vertex plans to initiate a dose-ranging study of VCH-222 as monotherapy in 1H09 and a trial that combines telaprevir with one of the compounds in 2H09. Goldman Sachs is getting paid again as it advises Vertex on the deal. [...] [...] -Vertex has acquired ViroChem Pharma for $375M. The deal includes $100M in cash for Canada-based ViroChem plus 9.9M Vertex shares. Vertex is interested in two of Virochem’s non-nucleoside HCV NS5B polymerase inhibitors, VCH-759, which is in a Phase 2 trial, and VCH-222, which is in a Phase 1. Vertex plans to initiate a dose-ranging study of VCH-222 as monotherapy in 1H09 and a trial that combines telaprevir with one of the compounds in 2H09. Goldman Sachs is getting paid again as it advises Vertex on the deal. [...]

]]>